Stifel Nicolaus Cuts Tempus AI (NASDAQ:TEM) Price Target to $50.00

Tempus AI (NASDAQ:TEM) had its price target trimmed by Stifel Nicolaus from $60.00 to $50.00 in a report issued on Monday, MarketBeat Ratings reports. The brokerage currently has a hold rating on the stock.

A number of other research analysts have also recently issued reports on the stock. Jefferies Financial Group assumed coverage on shares of Tempus AI in a research report on Monday, April 13th. They set an “underperform” rating and a $35.00 price target for the company. Guggenheim upped their price objective on shares of Tempus AI from $60.00 to $65.00 and gave the stock a “buy” rating in a report on Thursday, July 16th. Needham & Company LLC reaffirmed a “buy” rating and set a $75.00 target price on shares of Tempus AI in a research note on Friday, July 31st. Freedom Capital upgraded shares of Tempus AI to a “hold” rating in a report on Tuesday, June 30th. Finally, Lake Street Capital cut Tempus AI to a “hold” rating in a research report on Monday, July 20th. Nine analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $64.92.

Tempus AI Price Performance

TEM opened at $46.70 on Monday. The company has a current ratio of 3.30, a quick ratio of 3.16 and a debt-to-equity ratio of 3.06. The company has a market cap of $8.39 billion, a price-to-earnings ratio of -32.43 and a beta of 3.58. The stock has a fifty day simple moving average of $51.40 and a two-hundred day simple moving average of $52.12. Tempus AI has a 12-month low of $40.77 and a 12-month high of $104.32.

Tempus AI (NASDAQ:TEM) last announced its earnings results on Thursday, July 30th. The company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.10. The firm had revenue of $382.49 million for the quarter, compared to analysts’ expectations of $379.69 million. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The company’s quarterly revenue was up 21.6% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.22) EPS. Research analysts predict that Tempus AI will post -1.35 earnings per share for the current fiscal year.

Insider Activity at Tempus AI

In related news, CEO Eric P. Lefkofsky sold 250,000 shares of Tempus AI stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $42.06, for a total value of $10,515,000.00. Following the completion of the sale, the chief executive officer directly owned 200,000 shares in the company, valued at approximately $8,412,000. This trade represents a 55.56% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jennifer A. Doudna sold 2,673 shares of the business’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $55.00, for a total value of $147,015.00. Following the completion of the transaction, the director directly owned 25,942 shares of the company’s stock, valued at approximately $1,426,810. This trade represents a 9.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 723,981 shares of company stock valued at $34,879,442 over the last three months. 24.26% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. JPL Wealth Management LLC purchased a new stake in Tempus AI in the third quarter worth approximately $26,000. Los Angeles Capital Management LLC purchased a new stake in Tempus AI during the 4th quarter valued at $27,000. Harvest Fund Management Co. Ltd purchased a new stake in Tempus AI during the 3rd quarter valued at $38,000. Whittier Trust Co. raised its stake in Tempus AI by 190.0% during the 1st quarter. Whittier Trust Co. now owns 870 shares of the company’s stock valued at $41,000 after buying an additional 570 shares during the last quarter. Finally, EverSource Wealth Advisors LLC lifted its holdings in shares of Tempus AI by 88.8% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 691 shares of the company’s stock valued at $44,000 after buying an additional 325 shares during the period. 24.22% of the stock is owned by hedge funds and other institutional investors.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.